Core Viewpoint - Fortrea Holdings Inc. reported quarterly earnings of $0.19 per share, significantly exceeding the Zacks Consensus Estimate of $0.06 per share, and showing a turnaround from a loss of $0.03 per share a year ago, indicating strong performance in the latest quarter [1][2] Financial Performance - The company achieved revenues of $710.3 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 12.60% and reflecting an increase from $662.4 million in the same quarter last year [2] - Over the last four quarters, Fortrea has exceeded consensus EPS estimates two times and topped revenue estimates three times [2] Stock Performance - Fortrea Holdings Inc. shares have declined approximately 64.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.14 on revenues of $607.87 million, while for the current fiscal year, the estimate is $0.42 on revenues of $2.5 billion [7] - The outlook for the Medical - Biomedical and Genetics industry, where Fortrea operates, is currently in the bottom 42% of over 250 Zacks industries, which may impact stock performance [8]
Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates